The article “Emerging Drug Delivery Systems for Posterior Segment Disease” by David Levine, MD; Thomas A. Albini, MD; Howard F. Fine, MD, MHSc; and Steven Yeh, MD, which was published in the March issue of OSLI Retina (volume 51, number 3, pp. 132–135), has been amended to include factual corrections. An error in attribution of intraocular pressure (IOP) elevation related to Iluvien was identified subsequent to its original publication. The sentence stating, “Kiddee et al. demonstrated an elevation of IOP in 66% of patients treated with the low-dose Iluvien implant and 79% of patients treated with the high-dose Iluvien implant” is incorrect. The sentence should state, “Kiddee et al. demonstrated an elevation of IOP in 66% of patients treated with 0.59 fluocinolone acetonide and 79% of patients treated with 2.1 mg fluocinolone acetonide implant.” This IOP elevation is related to findings from a meta-analysis by Kiddee et al. related to the surgically implanted fluocinolone acetonide implant (Retisert; Bausch + Lomb, Rochester, NY), of which only the 0.59 mg implant is currently commercially available. The Iluvien implant refers to the 0.19 mg intravitreally injected fluocinolone acetonide implant and is not related to the rates of IOP elevation in this sentence. The online article and its erratum are considered the version of record. To view the article, click here.